Urgent

Rituximab infusion reaction and hypogammaglobulinaemia

Biologic infusion and immunoglobulin complications · Rheumatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Rituximab, widely used in vasculitis, lupus and refractory inflammatory arthritis, commonly causes cytokine-release infusion reactions during the first infusion and can lead to cumulative hypogammaglobulinaemia with infection risk. Reactions range from mild flushing to bronchospasm, hypotension and, rarely, anaphylaxis.

Red flags

  • Airway swelling, stridor or bronchospasm
  • Hypotension or collapse during infusion
  • Recurrent or severe infections (hypogammaglobulinaemia)
  • Features of hepatitis B reactivation (deranged LFTs)
  • Late rash, fever and arthralgia (serum sickness)

Assessment

Differential diagnosis

  • IgE-mediated anaphylaxis
  • Cytokine-release (infusion) reaction
  • Serum sickness (delayed)
  • Underlying sepsis
  • Tumour lysis (in lymphoproliferative disease)
  • Vasovagal reaction

Investigations

  • Observations during infusion (BP, saturations, temperature, airway)
  • Serum immunoglobulins (IgG/IgA/IgM) at baseline and before each cycle
  • FBC and B-cell/CD19 counts
  • Hepatitis B serology (HBsAg, anti-HBc) before treatment
  • Tryptase if anaphylaxis suspected
  • Infection screen if febrile or recurrent infections

Management

  • Pre-medicate before infusion to reduce reactions and start at a slow infusion rate
  • For a mild-moderate infusion reaction, pause or slow the infusion and give antihistamine and steroid, then restart slowly
  • For severe reaction (airway, hypotension, bronchospasm) stop the infusion and treat as anaphylaxis with adrenaline
  • Screen and manage hepatitis B before treatment to prevent reactivation (antiviral prophylaxis if required)
  • Monitor immunoglobulins periodically; investigate recurrent infections for secondary hypogammaglobulinaemia
  • Treat significant symptomatic hypogammaglobulinaemia with immunoglobulin replacement
  • Consider co-trimoxazole prophylaxis against PJP during intensive immunosuppression
  • Document the reaction severity and plan premedication/rate for future cycles

Drugs & doses

Methylprednisolone — 100 mg IV premedication 30 min before rituximab infusion
Chlorphenamine — 10 mg IV plus paracetamol 1 g PO as premedication/for mild reactions
Adrenaline — 500 micrograms (0.5 mL of 1:1000) IM for anaphylaxis, repeat after 5 min as needed
Normal immunoglobulin (IVIG) — replacement dosing (e.g. 0.4 g/kg every 3-4 weeks) for symptomatic hypogammaglobulinaemia
Entecavir / tenofovir — antiviral prophylaxis if hepatitis B core antibody positive (specialist-led)

Disposition

Manage mild reactions and continue infusion with monitoring; admit for anaphylaxis, significant infection or immunoglobulin complications.

Complications & pitfalls

  • Anaphylaxis / severe infusion reaction
  • Secondary hypogammaglobulinaemia with recurrent infection
  • Hepatitis B reactivation and fulminant hepatitis
  • Progressive multifocal leukoencephalopathy (rare)
  • Serum sickness and late neutropenia

Exam pearls

  • First-infusion cytokine-release reactions are common - premedicate and infuse slowly
  • Always check hepatitis B status before rituximab to prevent reactivation
  • Measure immunoglobulins before each cycle; cumulative hypogammaglobulinaemia increases infection risk
  • A true infusion reaction usually allows rechallenge at a slower rate, unlike anaphylaxis

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.